Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Gulf War Syndrome
Interventions
Lactulose Breath Test, Rifaximin, Placebo
Procedure · Drug
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Intestinal FDG Uptake
Interventions
Rifaximin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin 550 MG, Low FODMAP Diet
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Rifaximin in Preventing Campylobacteriosis

NCT02280044
Conditions
Dysentery, Diarrhea, Enteric Campylobacteriosis
Interventions
Rifaximin intervention, Placebo intervention
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Parkinson Disease
Interventions
Rifaximin, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Weight Loss
Interventions
Rifaximin
Drug
Lead sponsor
Bayhealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dover, Delaware
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Rifaximin With NAC in IBS-D

NCT04557215
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, N-acetylcysteine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Infant/ Neonate Lumbar Puncture
Interventions
Ultrasound assisted lumbar puncture
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
Oak Lawn, Illinois
Terminated Phase 2 Interventional Results available

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549
Conditions
Crohn Disease, Diabetic Gastroparesis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Not applicable Interventional Results available

Rifaximin in Minimal Hepatic Encephalopathy

NCT00533910
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, placebo
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
IgA Monoclonal Gammopathy of Undetermined Significance, Non-IgM Monoclonal Gammopathy of Undetermined Significance
Interventions
Rifaximin, Biospecimen Collection
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington